Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
8-26-2015 12:00 AM

Acute Sprint Interval Exercise Induces a Greater FGF-21 Response
in Comparison to Work-Matched Continuous Exercise
Blair M. Segsworth, The University of Western Ontario
Supervisor: Dr. Peter Lemon, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Kinesiology
© Blair M. Segsworth 2015

Follow this and additional works at: https://ir.lib.uwo.ca/etd

Recommended Citation
Segsworth, Blair M., "Acute Sprint Interval Exercise Induces a Greater FGF-21 Response in Comparison to
Work-Matched Continuous Exercise" (2015). Electronic Thesis and Dissertation Repository. 3254.
https://ir.lib.uwo.ca/etd/3254

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

ACUTE SPRINT INTERVAL EXERCISE INDUCES A GREATER FGF-21
RESPONSE IN COMPARISON TO WORK-MATCHED CONTINUOUS EXERCISE
(Thesis format: Monograph)

by

Blair Mackay Segsworth

Graduate Program in Kinesiology

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Blair Mackay Segsworth 2015

Abstract
Sprint interval training (SIT) has been associated with substantial reductions in body
fat. Recent evidence suggests that myokines (small protein compounds produced in
muscle) may promote the fat loss with SIT. The purpose of this project was to
compare the plasma accumulation of three myokines (IL-15, Irisin and FGF-21) with
sprint interval exercise (SIE) vs work-matched continuous exercise (CE). Nine male
subjects completed an acute SIE session consisting of four-30 second sprints and a
work-matched CE session. Both exercise sessions were completed on an
electromagnetically braked cycle ergometer. Blood samples were collected before
and at 5, 30, 90, and 180 min post exercise to determine any changes in plasma
myokine concentration. Plasma FGF-21 was increased at five (P=0.04) and 30
(P<0.001) min with SIE vs baseline and was increased at 30 min (P=0.03) when
compared to CE. Neither Il-15 nor Irisin were altered significantly although there
were some methodology concerns and intersubject variability was substantial so a
Type II Error might have occurred. These findings suggest that exercise intensity is
a key determinant of plasma FGF-21 accumulation and that FGF-21 may serve as a
surrogate measure for both sympathetic activation and exercise-induced lipolysis.
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1

Introduction

The current state of global health is at a crossroads between improvements in
longevity and infant survival and the looming crisis associated with the rising
rates of obesity. At this juncture, about 937 million people worldwide are
considered to be overweight and ~396 million considered obese. Further, these
numbers are projected to grow so that by the year 2030, it is expected that a
staggering 1.12 billion people will be obese (Kelly et al., 2008). Many
pharmacological interventions have been developed to battle this issue and its
comorbidities such as hypertension, dyslipidemia and diabetes; however, it may
be that the universal remedy to the obesity epidemic could simply involve
consistent physical activity. For example, regular exercise has been shown
previously to prevent excessive mass gain and even promote fat losses (up to
386 cubic centimetres of adipose tissue) in obese adults over an 8-wk period
(Keating et al., 2015). Unfortunately, regardless of these benefits, many people
are unable to maintain physically active lifestyles, citing the lack of time as a
major reason for ineffective quantities of exercise (Stutts, 2002). A possible
solution to this issue is the use of sprint interval training (SIT) which results in
significant fat loss and very brief time commitments (Hazell et al., 2014;
MacPherson et al., 2010).
Typically, sprint interval exercise (SIE) consists of four-six bouts of “all-out”
intensity sprinting with each bout of sprints separated by a four min rest interval,
often performed on a cycle ergometer (Burgomaster et al., 2005) but any
exercise mode appears to work. As little as three min of “all-out” sprinting per
week has been shown to increase activity of oxidative enzymes such as citrate
synthase, cytochrome oxidase IV and β-hydroxy acyl CoA dehydrogenase as
well as decreasing average 24-h blood glucose (Gillen et al., 2014). These trends
in glucose homeostasis also apply to clinical populations as similar exercise
modalities have caused reduced time spent with hyperglycemia both at rest and
post-prandial (Gillen et al., 2012). Further, regular SIE can cause significant
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improvements in body composition causing a decrease in fat mass and waist
circumference by 8% and 3.5%, respectively, while increasing lean mass by
1.5% over a 6 wk training period (Hazell at al., 2014). In terms of oxygen
consumption, just two min of SIE induces similar 24-h oxygen consumption as 30
min of continuous aerobic exercise (CE), despite SIE requiring 150% less in VO2
load during the actual exercise (Hazell et al., 2012). These findings indicate a
significant contribution to 24-h oxygen consumption due to an anaerobic exercise
component and/or a residual change in post exercise metabolism. This resulting
prolonged change in metabolism (increased baseline energy expenditure and/or
elevated fat catabolism) may explain some of the fat losses often observed with
SIT.
When compared to moderate intensity CE training, meta-analyses demonstrate
that SIT produces similar 8% increases in VO2max (Gist et al., 2013) due primarily
to an increase in mitochondrial density and the upregulation of oxidative
enzymes such as cytochrome oxidase IV and β-hydroxy acyl CoA
dehydrogenase (Sloth et al., 2013). Interestingly, SIT promotes similar changes
in exercise capacity vs CE with exercise volumes of ~10% and total exercise time
of ~21% (Gibala et al., 2006). Moreover and importantly, interval training, even
intense SIT has also been associated with higher ratings of perceived pleasure
when compared to CE (Bartlett et al., 2011).
Many of the peripheral adaptations to SIT are due to increased mitochondrial
content that occurs along with improved oxidative capacity (Jacobs et al., 2013,
Scalzo et al., 2014). On a molecular level, it is thought that the increased
mitochondrial biogenesis is caused by the phosphorylation of p38 MAPK and
AMPK which promotes an increase in PGC-1α mRNA content (Gibala et al.,
2008). This connection is critical as PGC-1α is known to be the master regulator
of mitochondrial biogenesis as well as many of the oxidative genes linked to
mitochondrial function (Wu et al., 1999). Although there is an established link
between SIT and the induction of oxidative adaptations, the precise mechanism
regulating these changes has not been elucidated fully. However, the
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biochemical signaling process responsible for the adaptations appears to be
more powerful because these metabolic changes are induced by substantially
less total work volume and time.
A new theoretical model describing the function of muscle has also been
described concurrently with the development of SIE as an effective exercise
mode. Like adipose tissue, skeletal muscle is now known to act much like an
endocrine organ, capable of secreting several hormonal signals to communicate
with a number of other body tissues (IIzuka et al., 2014, Pedersen and Febbraio,
2013). Rather than communicating via fat-soluble hormones, skeletal muscle
utilizes contraction-induced cytokines to implement functional changes
throughout the body (Pedersen and Febbraio, 2013). These have become known
as myokines because the tissue of origin for these cytokines is muscle and, as of
2014, there are at least 69 identified myokines within the secretome of muscle
(Catoire et al., 2014). One of the most well characterized myokines is IL-6,
traditionally a pro-inflammatory cytokine, it is increased chronically in the obese
(Pal et al., 2014). IL-6 is also elevated acutely following exercise and improves
insulin and glucose sensitivity through the up-regulation of glucagon-like peptide1 (Pal et al., 2014). Although much effort has been directed to the study of IL-6, a
new subgroup of myokines has been identified as perhaps playing a role in how
exercise promotes fat loss.
Irisin, Fibroblast Growth Factor-21 (FGF-21) and Interleukin-15 (IL-15) are three
novel myokines that have been implicated with fat metabolism, oxidation and
phenotypical changes. Specifically, Irisin promotes a brown/beige adipose
phenotype, in which an induction of gene related mitochondrial biogenesis (PGC1α, UCP-1, GLUT-4) has been reported (Vaughn et al., 2014, Huh et al., 2014).
Further, in conjunction with FGF-21, Irisin increases non-shivering
thermogenesis in beige/brown adipose via uncoupling of the electron transport
chain (Lee et al., 2014). Interestingly, non-shivering thermogenesis induction by
Irisin and FGF-21 are similar between both cold environmental conditions and
exercise, with greater plasma concentrations of the induced myokines found
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post-exercise (Lee et al., 2014). With respect to phenotype, beige/brown adipose
is advantageous because 60 g of brown adipose is capable of metabolizing ~4 kg
of white adipose over the course of a year (Virtanen et al., 2009). Moreover,
FGF-21 may also provide a substantial body fat reduction benefit in that it is
capable of increasing glucose uptake (Kharitonenkov et al., 2005), the
deacetylation and activation of PGC-1α (Fu et al., 2009), as well as help
coordinate the metabolic response to exercise-induced lipolysis (Lee et al., 2013,
Cuevas-Ramos et al., 2012).
Traditionally, IL-15 has been viewed as an anabolic myokine, capable of inducing
the accretion of myosin heavy chain proteins within human muscle cells
(Furmanczyk and Quinn, 2003) as well as assisting in lipid oxidation and storage.
The treatment of adipocytes with IL-15 can reduce lipid deposition by 50%
(Quinn et al., 2005), enhance the expression of PGC-1α in muscle cells, and
increase total mitochondrial volume (O’Connell and Pistilli, 2015). Interestingly,
mice over-expressing IL-15 have been shown to have lower resting RER, upregulation of PGC-1α, and increased oxidative muscle fibre content (Quinn et al.,
2013). Considering the role of these myokines in producing a more oxidative (βoxidation) phenotype, it is imperative to discern their role and induction postexercise.
Recently, Irisin, FGF-21 and IL-15 have been studied with some types of
exercise. For example, Irisin with both resistance (strength) and aerobic
(endurance) exercise paradigms and appears to respond to intensity of exercise
in a dose-dependent manner (Huh et al., 2012, Huh et al., 2014). Apparently
acute sprint exercise causes Irisin to accumulate at a concentration 15% greater
than an endurance bout (Huh et al., 2014); however, in this study the exercise
conditions were not matched for total work output so these data may be
confounded. FGF-21 has been reported to increase one h after an acute bout of
modest aerobic exercise (50% of VO2max), yet the effect of acute sprinting on the
secretion of FGF-21 has not been researched extensively (Kim et al., 2013). In
this regard, FGF-21 has only been studied in a SIT regimen consisting of nine
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sessions of four-eight 30s sprinting bouts on a cycle ergometer (Scalzo et al.,
2014). Similarly, the relationship between exercise and the induction of IL-15 in
humans has not been well documented but significant increases in circulating IL15 after with moderate intensity (50-70% of VO2max) cycling or running have been
reported (Christiansen et al., 2013, Tamura et al., 2011). There have been no
studies profiling the acute effect of SIE on the secretion of IL-15.
Therefore, the aim of this thesis was to conduct a work-matched comparison
(per-joule basis) of Irisin, FGF-21 and IL-15 between acute SIE and CE to
determine which exercise modality induces the greatest myokine response. In
essence this will determine the role of exercise intensity- defined as a percentage
of VO2max- in the accumulation of plasma myokines. It was hypothesized that SIE
would promote the greatest increase in plasma Irisin, FGF-21 and IL-15 and
thereby perhaps be the mechanistic link between SIE and its noted ability to
stimulate both oxidative adjustments to exercise and the resulting positive
changes in body composition.
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2

Literature Review

2.1 Sprint Interval Exercise in Humans
Typically, sprint interval exercise (SIE) is defined as four-six, 30 sec “all-out”
sprints separated by a four min recovery interval that may be either active or
passive (Burgomaster et al., 2005). These sprints are often repeat Wingate tests,
i.e., 30 sec sprints on a cycle ergometer at a resistance of eight-10% of body
mass (Burgomaster et al., 2005, Hazell et al., 2012). Two min of SIE has been
reported to induce a similar oxygen consumption (VO2) over a 24-h period as a
30-min continuous, moderate intensity endurance bout of exercise (CE) (Hazell
et al., 2012). In the aforementioned study, it is interesting to note that, although
the oxygen consumption was significantly less during the SIE session, the 24-h
consumption was not different vs the 30-min endurance exercise, indicating that
SIE may cause biochemical or physiological changes that induce an extended
increased oxygen consumption post exercise. Further, in both men and women,
SIE has been shown to result in substantial body fat loss despite very little
training time. In women, SlT on a self-propelled treadmill three times per wk for
six wk reduced fat mass by 8%, waist circumference by 3.5% and also increased
maximal oxygen consumption by 8.7% (Hazell et al., 2014). During this training, it
is noteworthy that the participants did not appear to change their diet
significantly. In men, a similar training protocol involving a progressive increase
in sprints (from four to six over six wk) induced a 3kg loss of body fat
(MacPherson et al., 2010). Further, in a subsequent study, acute SIE had little
effect on energy intake despite increased appetite and energy expenditure
(Beaulieu et al., 2014). These observations indicate that changes in food intake
are not the main factor responsible for the improved body composition.
Another study with untrained, middle aged men who underwent SIT, consisting of
four-six bouts of 30 sec all-out sprints for a total of just six training sessions
observed an increase in VO2 peak of 6%, as well as an increase in muscle
glucose uptake (Eskelinen et al., 2015). Interestingly, the effect of increased
glucose uptake was isolated to the quadriceps femoris muscles. When compared

7

to other muscle groups the changes in glucose and fatty acid uptake during
exercise was only present within the quadriceps, indicating a local effect of the
SIT perhaps induced by a form of autocrine/paracrine signaling. All four muscles
of the quadriceps responded to SIT, while in comparison, only the vastus lateralis
and vastus medialis responded to moderate intensity exercise (Eskelinen et al.,
2015).
Metabolically, acute SIE has resulted in increased phosphorylation of AMPK and
p38MAPK immediately after four bouts of 30-sec sprints (Gibala et al., 2008). In
the same study there was also a two-fold up-regulation of PGC-1α mRNA at
three h into recovery. Since SIE was capable of inducing an increase in PGC-1α
and the aforementioned regulators of oxidative metabolism, the authors
concluded that SIE was also capable of increasing mitochondrial content.
Therefore these findings contribute further to the idea that SIE is capable of
inducing similar increases in mitochondrial content and metabolic remodeling to
that caused by traditional endurance training. To support these findings, electron
transport chain protein cytochrome c oxidase, a marker for mitochondrial content,
has been shown to increase with SIT (Gibala et al, 2006). Another study using 60
sec intervals have found increases in cytochrome c oxidase content, a
concurrent 7.9% increase in VO2max, and a 5.1% increase in mean power output
(Jacobs et al., 2013). In a similar study, Perry et al. (2008) observed an 18%
increase in cytochrome c, increases in B-hydroxyacyl-CoA dehydrogenase, and
GLUT4 content within muscle after the completion of a high intensity interval
training regime consisting of 10 x four min intervals at 90% VO2max, three times
per wk, for six wk. Further, during 60% VO2 peak exercise there was a 60%
increase in fat oxidation after six wk of training when compared to pre-training
values at the same intensity. These findings indicate that high-intensity spectrum
training such as SIT may induce long-term changes in the efficacy of energy
substrate utilization during exercise.
In a meta-analysis of the cardiovascular adaptations to SIT, Gist et al. (2013)
found that SIT and moderate-intensity continuous interval training were similar in
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their relative ability to increase VO2max. However, there was a 20% reduction in
the time required to accomplish these endpoints with SIT. These findings are
supported by another meta-analysis, which found that VO2max increases in a
range of four-13% with SIT over two-eight wk (Sloth et al., 2013). It was also
shown that there are similar changes in exercise performance, glycemic control
and insulin sensitivity with SIT when compared to more traditional high-volume
training regimes (Sloth et al., 2013). These findings suggest that there may be
separate biochemical pathways or an amplification of factors that are inherent
within SIT, making it more efficient at inducing the benefits associated with
exercise.
The effect of SIT on the secretion of plasma cytokines/myokines is also
important. As outlined above, SIT has been observed to decrease the resting
plasma concentrations of FGF-21, after nine sessions of four-eight, 30 sec bouts
of all out sprints (Scalzo et al., 2014). Under the same training program, Irisin has
a sexually dimorphic response, increasing in women after SIT and decreasing in
men (Scalzo et al., 2014), while SIE increases plasma Irisin acutely (Huh et al.,
2014). Outside of the aforementioned myokines, SIE has also been reported to
have an effect on a wide variety of plasma inflammatory markers. Meckel et al.
(2011) showed that SIE increases both pro- and anti-inflammatory factors such
as Il-1 and IL-6 immediately after a series of successive sprints of 100-400
metres, while IL-6 remained elevated one h into recovery. These data suggest
that along with other cyto/myokines, there may be a global response to sprint
exercise, rather than the production of a single subset of secreted myokines. On
the other hand, SIT has also been shown to have no effect on resting plasma
myokines IL-6, IL-10 and C-reactive protein after 2 wk of thrice weekly bouts of
four-six 30s sprints (Hovanloo et al., 2013). It is difficult to determine the long
term effects of SIT on plasma protein concentrations because there are such
divergent results in the effect of SIT and plasma inflammation markers. Although
there are a limited number of studies presented focusing on the effect of SIE on
myokine concentrations, it is apparent that there is a gap within the literature and
this must be addressed in the context of both SIE and SIT.
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In conclusion, SIE is a powerful exercise modality that is capable of inducing
similar benefits as traditional endurance exercise with far less total energy and
time commitment. It appears that SIE mediates these functions though the upregulation of mitochondrial transcription factors as well as supporting
mitochondrial biogenesis and growth. However, is it unclear by which
mechanisms that these processes occur. The effect of SIE on plasma
inflammatory markers and myokines has not been studied systematically in the
literature and thus requires attention.

2.2

Irisin

In the groundbreaking study first describing Irisin, Boström et al. (2012) found
that a product of the proteolytic cleavage of the skeletal muscle integral
membrane protein fibronectin type 3 domain containing 5 (FNDC5) was secreted
into the bloodstream during exercise. Given the name Irisin for the Greek
messenger goddess Iris, this myokine circulates as a 112-amino acid protein
(Wrann et al., 2013). The exact process by which FNDC5 is cleaved and
released into the bloodstream remains unclear, but it is postulated to be similar in
fashion to other transmembrane polypeptide hormones such as Transforming
Growth Factor-α (Boström et al., 2012). Previous biochemical studies have
shown that while Irisin is a 16 stranded β-sheet dimer of two cleaved FNDC5
proteins for intercellular signaling, there is also a dimerization of FNDC5
endodomains for intracellular cell signaling (Schumacher et al, 2013). This leads
to the possibility that activation of the Irisin receptor can induce both endocrine
functions within a whole organism and autocrine functions on skeletal muscle.
Irisin is thought to mediate its activity through the master regulator of
mitochondrial biogenesis, PGC-1α, and morphogenic changes due to Irisin are
believed to be mediated by changes in ERK and p38 MAPK regulation (Zhang et
al., 2014).
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2.2.1

Cell Studies

Irisin is believed to be sourced directly from skeletal muscle cells, contributing to
72% of all circulating Irisin (Boström et al., 2012; Roca-Rivada et al., 2013).
However, this assumption may be subject to change. Using
immunohistochemistry to stain for Irisin within different cell cultures taken from
human cadaveric tissue, Aydin et al. (2014), found that the main source of Irisin
is not from skeletal muscle, but rather from the nerve sheaths that spread within
muscle tissue with smaller other contributions derived from the perimysium and
epimysium. Among the most responsive human tissues were the testis,
pancreas, liver, spleen, brain, stomach and cardiac tissues. By following the
staining patterns of Irisin and their tissue relationships, Aydin et al. (2014)
concluded that Irisin may play an important role in hypothalamic-pituitary-gonadal
axis.
Further, Irisin has been shown the be produced and secreted into cell media by
both human and C2C12 myocytes at rest, yet electrical pulse stimulation has
been shown to cause no significant increase in FNDC5 gene expression
(Raschke et al., 2013). Considering that Irisin has been shown to be related
inversely to PCr and ATP concentrations within muscle tissue (Huh et al., 2012)
and its downstream effects can be nullified by AMPK inhibitor, Compound C (Huh
et al., 2014), it may be that the secretion of Irisin is dependent on the accretion of
exercise-induced metabolites, rather than by simple muscular contraction.
Tissues treated with Irisin have shown a wide range of effects. Human muscle
cells taken from biopsies of obese individuals treated with Irisin produced
increased IGF-1 and decreased myostatin mRNA expression (Huh et al., 2014).
In adipose cells derived from the same human donors, both physiological and
below-normal concentrations of Irisin inhibited lipid accumulation and significantly
inhibited fatty acid synthase. Moreover, after eight days of Irisin treatment, mRNA
of genes for thermogenic programs such as cell death-inducing DFFA-like
effector A (CIDEA) and uncoupling protein 1 (UCP-1) increased, as well as
markers of mitochondrial biogenesis, PGC-1α and TFAM (Huh et al., 2014). In
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the same study, adipose triglyceride lipase was also up regulated, indicating that
with the increased expression of UCP1, there is also an increased use of fat
substrate for oxidation and heat production. As a final measure, Irisin treatment
inhibited adipocyte differentiation and maturation in human and mouse preadipocytes.
As suggested by biochemical characteristics, it has been shown through in-vitro
studies that Irisin exerts an autocrine effect on skeletal muscle. For example,
C2C12 myocytes treated with Irisin have an increase in expression of genes
related to mitochondrial biogenesis including PGC-1α, NRF-1, TFAM, GLUT4,
UCP3 and Irisin (Vaughan et al., 2014). The noted increase in Irisin gene
expression suggests that circulating Irisin exerts an autocrine, positive feedback
loop back on skeletal muscle. The Irisin-treated myocytes also had a greater
amount of global mitochondrial organelle content and expressed a greater total
carbohydrate oxidation and decreased lactate production (Vaughan et al., 2014).
Combined with its positive feedback loop and increased mitochondrial
biogenesis, it appears that Irisin exerts a shift to an oxidative phenotype within
skeletal muscle and adipose tissue. It is important that the secreted portion of
Irisin is also highly conserved within all mammalian species; mouse and human
Irisin are 100% identical (Bostrom et al., 2012). Recently, it has been shown that
both shivering and exercise cause a similar secretion of Irisin, although
marginally greater plasma concentrations are achieved through exercise (Lee et
al., 2014). Combined with another myokine, FGF21; Irisin induces the browning
of adipose as well as non-shivering thermogenesis in response to lower body
temperature in human subjects (Lee et al., 2014). From these experimental data
and the conservation of Irisin structure through mammals, it is believed that Irisin
is a remnant of evolutionary homology to cold changes within the environment.
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2.2.2

Animal Studies

In mice, submaximal treadmill exercise to volitional fatigue induces a two fold
increase in plasma Irisin concentration, while free running and control mice
showed no increase in plasma Irisin (Brenmoehl et al., 2014). There were also
higher concentrations of Irisin within homogenates of femoral muscles, when
compared to those of crus (forelimb) muscles in mice. Irisin was also not
correlated with the running distance of the either the voluntary free-wheel running
or the treadmill test, suggesting the determinant of the Irisin response may be
exercise intensity not duration (Brenmoehl et al., 2014). Through
immunohistochemical staining, it was also shown that Irisin was localized around
muscle cell membranes and intercellular spaces. This corresponds with the
findings of Aydin et al. (2014) who suggested Irisin might be a product of the
nerve sheaths permeating through muscle tissue with smaller contributions also
originating from the epimysium and perimysium. Of the various muscle types,
slow/oxidative fibres secrete ~40% more Irisin than glycolytic fibres (Roca-Rivada
et al., 2013). Further, in a separate study, three wk of endurance training reduced
the concentration of Irisin in plasma, suggesting a role of muscle and exercise
training in the down-regulation of Irisin signaling (Roca-Rivada et al., 2013).
Animal studies have also shown that adipose tissue may play a role in Irisin
homeostasis. Roca-Rivada et al. (2013), suggested that a secreted form of
FNDC5 in rats is also produced by adipose tissues and that obese rats oversecrete this protein in adipose. These findings may illustrate a feedback
mechanism between muscle and adipose for Irisin and further, that there may be
an Irisin resistance during obesity and other metabolic disorders. Comparing
adipose types, subcutaneous adipose secretes 40% more FNDC5/Irisin
compared to visceral fat. Contrary to these findings, Roberts et al. (2013) found
that circulating Irisin tended to be lower in obese/diabetic prone Otsuka LongEvans Tukushima Fatty (OELTF) rats. Triceps brachii biopsies showed that
FNDC5 and PGC-1α mRNA were found to be 50% and 40% less in OLETF rats,
respectively and were correlated with body composition. Total body fat and
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plasma Leptin concentrations are associated positively with greater skeletal
muscle FNDC5 mRNA expression. It is speculated that Leptin may be a key in
the cross talk between muscle and fat because Leptin increases PGC-1α through
AMPK mediated signaling. Therefore, Irisin may serve as a compensatory
mechanism to stimulate thermogenesis and increase fat loss in the obese state
(Roberts et al., 2013).
A unique and interesting role of Irisin may be located in the central nervous
system. Wrann et al. (2013) have proposed the link between exercise and brain
BDNF production to be Irisin and the FNDC5 receptor. Via endurance exercise,
activation of FNDC5 within the hippocampus of mice was observed to cause an
increase in BDNF mRNA. It is believed that the effects of FNDC5 on BDNF
transcription is mediated through a complex formed by PGC-1α and Estrogen
Related Receptor-α (ERRα) as both PGC-1α and ERRα knockout mice had
dramatically reduced FNDC5 activity (Wrann et al., 2013). Hippocampal
expression of BDNF was also shown to have a negative feedback effect on
FNDC5 activity within the brain, indicating a homeostatic loop between FNDC5
and BDNF. The most significant finding from Wrann et al. (2013), is that the
peripheral delivery of FNDC5 to the liver via adenoviral vectors caused an
increase in the central expression of BDNF. This is a clear indication that a
secreted factor influences the central activity of FNDC5 and implies a
communication axis between exercising muscle, the liver and the brain; however,
it has yet to be determined if the main signaling molecule is Irisin or another
cleavage product from muscle FNDC5 (Wrann et al., 2013).
As promising as the animal studies surrounding Irisin may be, it is often difficult
to translate research from rodent studies to humans. Raschke et al. (2013)
outlined the fact that there is a mutation in a start codon of the FNDC5 gene
between rodents and humans. This mutated form of FNDC5 has low translation
efficiency in humans and only resulted in 1% of full length FNDC5 protein, when
compared to rodents. Raschke et al. (2013) also found that FNDC5 gene
expression was not increased during in-vitro electrical pulse stimulation of
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primary skeletal muscle cells. As previously stated, these data must be taken
with some skepticism because electrical pulse stimulation is far from exercise
and often does not result in the accretion of exercise metabolites. Many of these
metabolites such as AMP and the subsequent activation of AMPK are implicated
in the activation of FNDC5 gene pathways and secretion of Irisin into the
bloodstream.

2.2.3

Human Studies

Many studies have profiled the existence of Irisin and its association with
exercise. While studying the physiological variation in plasma Irisin, Anastasilakis
et al. (2014), found that a diurnal rhythm of Irisin exists, with maximum plasma
concentrations being reached at 2100h and minimums at 600h. Interestingly, this
day-night rhythm is opposite of FGF-21 (Anastasilakis et al., 2014). It was
suggested that the inverse relationship between plasma Irisin and FGF-21
concentrations may be due to temperature, where Irisin plays a role in the
formation of brown adipose tissue (Vaughn et al., 2014) and FGF-21 then
activates that tissue for heat production during lower overnight temperatures as
outlined by Anastasilakis et al. (2014) and Lee et al. (2014.
Huh et al. (2012), using biceps circumference as a gauge, showed that muscle
mass was the single greatest indicator of circulating plasma Irisin. Plasma Irisin
is correlated positively with BMI and negatively correlated with age, insulin, and
cholesterol within the blood. Subjects who had undergone bariatric surgery were
observed to have a reduction in both total and lean body mass which coincided
with a subsequent decrease in resting plasma Irisin when compared to presurgery (Huh et al., 2012). It was also shown that a 7% reduction in body mass
due to a hypocaloric diet also caused a reduction in plasma Irisin (De La Iglesia
et al., 2014), suggesting a relationship between Irisin production and skeletal
muscle. Young, male, athletes were found to have the highest resting plasma
concentrations of Irisin (Huh et al., 2012); however, when adjusted for lean body
mass, females were found have even greater resting Irisin concentrations
(Anastasilakis et al., 2014). In a separate study involving a population of 17 post-
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menopausal women, Swick, Orena, & O’Connor (2013) found that the subgroup
of women who had daily energy expenditures greater than the predicted values
of energy expenditure∙kg fat free mass-1 also had the greatest concentrations of
resting plasma Irisin. From this information it was hypothesized that the
increased energy expenditure may be due at least partially to the browning effect
of Irisin on adipose tissues.
With respect to Irisin, the effect of exercise and exercise intensity has been
studied but remains controversial. Acutely, Irisin has been shown to increase
within the blood in response to endurance exercise by about 20% (Anastasilakis
et al., 2014). Sprint interval exercise has also been shown to induce an increase
in plasma Irisin (Huh et al., 2012). For example, three sets of two, 80 metre
sprints with 20 min of rest between sets induced an 18% increase in plasma
Irisin, 30 min after exercise. In the same study, the increase in Irisin was
correlated with the decrease in ATP and PCr, while having no relationship with
ADP or pyruvate. The same sprint protocol was conducted three times per wk
over an eight wk period and at the conclusion of the training the acute induction
of Irisin immediately after the sprints Irisin was no longer significant. Interestingly,
there was also no acute decrease in ATP, suggesting that Irisin may respond to
ATP depletion and that the intensity of the sprint exercise was no longer great
enough to induce an Irisin response (Huh et al., 2012). Plasma Irisin has also
been observed to be elevated after acute static exercise performed on vibration
platforms in untrained women (Huh et al., 2014). However, contrary to their
previous findings, Huh et al. (2014) found that the acute Irisin response to
exercise was maintained after nine wk of vibration training suggesting that
vibration may be different than exercise per se.
Huh et al. (2014) further described Irisin as being present in lower concentrations
in both physically active and older individuals at rest, when compared to
sedentary or young individuals. However, acute increases in plasma Irisin
immediately after exercise were unrelated to fitness or age. In a comparison
between five, 50 metre swimming sprints and a single 2,000 metre endurance

16

swim, Huh et al. (2014), found that Irisin was elevated in plasma by 30%
immediately after and by 15% one h after the sprint condition, while the
endurance group showed no significant change. As stated earlier, there was no
interaction between fitness, age and the increase in plasma Irisin, thus the
authors concluded that, regardless of baseline plasma Irisin, the response to
acute exercise is similar (Huh et al., 2014). Moreover, similar plasma Irisin
concentrations have been found with VO2max treadmill tests (34% increase in
plasma Irisin) as with 10 min at 70% VO2max or 10 min at an absolute (75W)
workloads (Daskaloupolou et al., 2014). Using 90 min of continuous treadmill
running, Kraemer et al. (2014) reported that plasma Irisin was only significantly
different from rest at 54 min of exercise rather than at the completion of the 90
min exercise bout. These findings indicate that the Irisin response of muscle may
only be limited to a small window of activity after the initial onset of exercise.
Lastly, Tsuchiya et al. (2014) showed that 20 min of high intensity exercise at
80% VO2max produced plasma Irisin concentrations greater than pre-exercise
values at six and 19h after exercise by 18% and 23%, respectively. In contrast,
40 min of low intensity exercise (40% VO2 max) caused no increase from preexercise values. Further, low intensity exercise produced a decrease in plasma
Irisin. The findings of Tsuchiya et al., (2014) suggest that the Irisin response from
muscle may, although unlikely, be delayed in nature because there was no Irisin
response until six hours post-exercise.
The Irisin response to both endurance and sprint training is not nearly as clear as
the acute effect of exercise. In the original paper outlining the existence of Irisin,
Boström et al. (2012) found that endurance training (10 wk of four-five sessions
of 20-35 min cycling at 65% VO2max per wk) promoted a twofold increase in
plasma Irisin concentrations in humans at rest. SIT has been shown to decrease
resting plasma Irisin in males, while increasing resting plasma Irisin in females
Scalzo et al. (2014). Scalzo et al. (2014) also determined that the secretion of
Irisin into the plasma is unaffected by the sympathetic stimulation associated with
exercise as there were no changes in plasma Irisin due to either inhibition by
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clonidine (a central acting adrenergic agonist), or by hypoxia- induced
sympathetic activation.
In terms of resistance exercise, 12 wk of progressive resistance training in
untrained women had no effect on FNDC5 expression or serum Irisin (Ellefsen et
al., 2014). Further, it was found that FNDC5 expression was closely correlated to
the proportion of aerobic muscle fibres pre-training, but this correlation
disappeared post-training. In the untrained state, Irisin appeared to be correlated
to both lean body mass and fat mass, yet in the trained state, was only related to
fat mass (Ellefsen et al., 2014). These findings suggest that there may be a
change in Irisin regulation within muscle due to strength training.
There is a great deal of controversy surrounding the existence of Irisin and its
production as a result of exercise. Pekkala et al. (2013), have shown that there is
an inconsistent Irisin response to resistance and low intensity endurance training.
No differences in FNDC5 expression in muscle were found after 21 wk of aerobic
or aerobic/resistance combined training; however, an acute high-intensity
resistance bout increased PGC-1a mRNA expression four-fold in older men,
while increasing FNDC5 mRNA expression 1.4 times in young men, reinforcing
the notion that the function of FNDC5 and Irisin, if any, may only be acute in
nature. Hecksteden et al. (2013) showed similar results indicating that there were
no changes in resting Irisin after a 26 wk combined resistance and aerobic
training program. Further, they also noted that there was an effect of storage time
for Irisin, where longer time in freeze storage resulted in reduced Irisin
concentrations as determined by ELISA. Hecksteden et al. (2013) found that at 20°C, there was a degradation slope that was calculated to be 0.184 ng∙ml-1∙day1

. Using only gene chip analysis, (Timmons, Baar, Davidsen, & Atherton, 2012)

showed that out of 200 subjects, an increase in FNDC5 expression was only
evident in a small subgroup of highly active elderly subjects. After undergoing
aerobic or resistance training protocols, there was no increase in FNDC5
expression, while an increase in PGC-1α was consistent throughout all groups.
These data allowed Timmons et al. (2012) to conclude that FNDC5 and Irisin are
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perhaps non-existent in humans or, as claimed by (Raschke et al., 2013), a
pseudo gene. In a rebuttal published in Nature, (Boström et al., 2012) responded
to these issues, stating that gene chip analyses are not a robust quantitative
measure and are more qualitative in design, limiting any conclusions based on
the change in FNDC5 transcription. It must also be noted that the subjects for
Timmons et al. (2012), had undergone endurance exercise training and the acute
secretion of Irisin was not evaluated. From many of the studies reviewed, it
appears that FNDC5 activation and the subsequent release of Irisin is acute in
nature and that it may be the chronic exposure to the pulsatile release of Irisin
during exercise that is the true mediator of any beneficial effects.
Regardless of what controversy that may exist, it is safe to conclude that Irisin is
indeed a myokine that is induced during exercise. It is likely that any secretion of
Irisin is dependent on total muscle mass, but presents a dichotomy between men
and women, where females appear to have greater resting concentrations and
increase plasma Irisin as a response to exercise training. Irisin appears to be
responsible for morphogenic changes within adipose tissue, being capable of
inducing a brown/beige adipose phenotype. It is likely that the secretion of Irisin
is dependent on the intensity of exercise as displayed by the studies featuring
SIE; however, this concept requires further attention.
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2.3

Fibroblast Growth Factor-21

Discovered by Nishimura et al. (2000), Fibroblast Growth Factor-21 (FGF-21)
was identified as a 210 amino acid protein and found to be expressed within the
liver. The amino acid sequence of FGF-21 is almost entirely identical between
mice and humans and relative to the other Fibroblast Growth Factors, is most
similar to FGF-19 in structure. FGF-21 responds to starvation and stress within
the liver. Unlike most FGF family members that have autrocrine or paracrine
functions requiring heparin sulfate binding, FGF-21 is capable of exerting
endocrine effects and is dependent on β-Klotho for receptor binding (Bae, Kim, &
Park, 2014). Interestingly, β-Klotho is almost exclusively expressed within the
liver, adipose tissue and pancreas, indicating that the endocrine target tissues of
FGF-21 are most likely to be the pancreas and adipose tissue.

2.3.1

Cell Studies

Many cell studies have focused on the capabilities of FGF-21 as a signaling
molecule as well as the nature of its regulation. Using Murine C2C12 myocytes,
Ribas et al. (2012), showed that FGF-21 was induced upon the differentiation of
myoblasts into myotubes. It was found that the transcription co-factor, MyoD,
controls FGF21 mRNA expression as the overexpression of MyoD caused an
induction of both FGF-21 mRNA and an increase in FGF-21 protein within the
cell media (Ribas et al., 2012). Mitochondrial dysfunction induced by oligomycinan inhibitor of complex II within the electron transport chain- also showed an
increased amount of FGF-21 protein production. This response was blunted by
the presence of reactive oxygen species scavenger Trolox, a soluble form of
Vitamin E. These data implicate FGF-21 as a marker for mitochondrial
dysfunction or stress. FGF-21 has been implicated as a possible avenue for the
treatment of Metabolic Syndrome, as the treatment of FGF-21 in both mouse
3T3-L1 adipocytes and human primary adipocytes causes an increase in glucose
uptake (Kharitonenkov et al., 2005).
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2.3.2

Animal Studies

The relationship between energy homeostasis and FGF-21 has been thoroughly
studied in both rats and mice. In conjunction with their evaluation of the effects of
FGF-21 on adipocytes, Kharitonenkov et al. (2005), also showed that the
therapeutic administration of FGF-21 was capable of reducing plasma
triglycerides and blood glucose to normal concentrations in both leptin-deficient
and diabetic-obese rats. Obesity is also implicated to be an FGF-21 resistant
state as Fisher et al. (2010), showed that diet-induced obese rats had elevated
resting plasma FGF-21 and that rats treated with FGF-21 have a reduced
response to treatment as measured by the phosphorylation of ERK 1/2. It may be
that this is caused by the up regulation of micro RNA-43a (miR-43a) (Fu et al.,
2014). MiR-34a was shown to be a key in the inhibitor of FGF-21 receptor
components and may explain the FGF-21 resistance that is observed within the
obese state. Downregulation of this micro RNA by the use of the anti-sense
strand for miR-43a also showed improved lipid and glucose profiles and
promoted the formation of brown and beige adipose tissue (Fu et al., 2014). In
addition, Fu et al. (2014) also showed that FGF-21 is a key mechanism for the
deacetylation and activation of the PGC-1α gene and its subsequent effects in
promoting an oxidative phenotype through mitochondrial biogenesis. The authors
concluded that FGF-21 may exert this effect through increasing the activity of the
enzyme AMPK.
FGF-21 has been reported to also be involved in the response to starvation and
malnutrition. Kubicky et al. (2012), showed that with four wk of food restriction,
wild type mice had decreased body mass and tibial growth when compared to
FGF-21 knockout mice. The knockout mice showed normal growth patterns, but
these differences from wild type were abrogated when they were treated with
daily recombinant FGF-21. In the food restricted group, FGF-21 mRNA was upregulated in comparison to a group feeding ad libitum as well as a reduction in
circulating growth hormone and growth hormone receptor protein at the tibial
growth plate, indicating that FGF-21 reduces the functionality of growth hormone
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during starvation (Kubicky et al., 2012). The authors concluded from these data
that FGF-21 plays a causative role in reducing growth in malnutrition as an
adaptive stress response. In addition to these findings, Laeger et al. (2014) found
that circulating FGF-21 in rats and mice increased 10 fold while on a low-protein,
isoenergetic diet when compared to controls. Protein restriction in humans also
caused an increase in circulating FGF-21, inducing a 121% increase in
circulating FGF-21 after 28 days on a low-protein diet. FGF-21 was found to be
responsible for the behavioural adaptations to low-protein diet, where wild-type
rats increased food intake and energy expenditure while FGF-21 knockout mice
showed no changes in eating behaviour or energy expenditure. Over the course
of the diet, the FGF-21 knockout mice incurred a significant increase in body and
fat mass, further implicating that FGF-21 restricts body mass and assists in
regulating metabolism (Kubicky et al., 2012). It is thought that this regulation is
part of the liver-brain axis, where fasting has been shown to cause FGF-21 to be
released from the liver and activates downstream hypothalamic ERK1/2.
Subsequently, this increases the expression of corticotrophin releasing hormone
and corticosterone, increasing the rate of gluconeogenesis within the liver (Liang
et al., 2014).
Transgenic mice over expressing the thermogenic protein UCP-1, showed an
increase in the induction of the FGF-21 gene and also had a fivefold increase in
circulating FGF-21 protein (Keipert et al., 2013). Interestingly, the treatment of
white adipocytes with the serum of the UCP-1 transgenic mice also caused the
expression of UCP-1 within the wildtype adipocytes, indicating that FGF-21 is
likely a cause for morphogenic changes that occur within adipose tissue (Kiepert
et al., 2013). In support of the findings by Kubicky et al. (2012) and Keipert et al.
(2013) also described that the UCP-1 transgenic mice also had reduced bone
growth and smaller overall size, a key indication of the growth restriction that can
be induced by FGF-21.
Very little has been studied in terms of the relationship between exercise and
FGF-21 in animal models. A progressive ramp exercise test for 60 min or until
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reaching exhaustion caused a significant increase in plasma FGF-21 in mice
(Kim et al., 2013). There was no significant increase in FGF-21 mRNA in muscle,
but there was a significant increase in hepatic FGF-21 mRNA. PPAR-α and
ATF4, known positive regulators of FGF-21, were also elevated in the exercised
mice. These data indicate that the FFA released during exercise may be the
cause of the observed increase in plasma FGF-21 because PPAR-α is heavily
regulated by the presence of free fatty acids (FFA) (Kim et al., 2013). The
authors also concluded that it is also likely that FGF-21 is not a true myokine, but
is secreted as a result of lipolysis induced by exercise.

2.3.3

Human Studies

FGF-21 in humans appears to behave similarly to the findings in both animal and
cellular studies. In human subjects with specific mitochondrial myopathies such
as lacking Iron-Sulfur cross bridges, FGF-21 protein has been reported to be
circulating at greater concentrations (Crooks et al., 2013). Many of these
myopathies act at Complex II of the electron transport chain, which is in
accordance with the findings of Ribas et al. (2012), who used oligomycin to
inhibit Complex II and induce an FGF-21 response. These studies indicate that
FGF-21 may be a sensor for the energy availability or productive capabilities of
the cell.
A diurnal rhythm of FGF-21 exists, where plasma concentrations peak at 0800h
and are lowest at 1700h, with a half life of ~two h in humans (Lee et al., 2013;
Scalzo et al., 2014). A study investigating the effect of ambient temperature on
the secretion of FGF-21 found cooler temperatures induced a far greater FGF-21
response and the change in FGF-21 correlated positively with changes in
glycerol, an indicator of FFA (Lee et al., 2013). Once again these findings
indicate FGF-21 may be a consequence of FFA circulating in the body, helping
orchestrate a response to energy substrate availability. Moreover, when
examining patients with metabolic syndrome, FGF-21 was elevated at rest
(Bobbert et al., 2013). When adjusted for age, sex, BMI, fasting glucose and
cholesterol, FGF-21 remained an independent predictor of metabolic syndrome.
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This knowledge allowed the authors to conclude that FGF-21 may act to
counterbalance very early pathophysiological conditions such as elevated
plasma lipids and is thus elevated earlier on in the development of metabolic
syndrome (Bobbert et al., 2013). In men, it was found that plasma FGF-21 is
negatively related to cardiorespiratory fitness as defined as peak VO 2 (Taniguchi
et al., 2014). These data support the findings of Scalzo et al. (2014), who found
that aerobic training caused a reduction in resting FGF-21 concentrations,
indicating that there may be an inverse relationship between aerobic fitness and
resting FGF-21 plasma concentrations. Alternatively, FGF-21 and visceral
adipose were positively related. These results suggest that as visceral fat
increases within the body and its associated consequential increase of FFA
within the blood, so will FGF-21(Taniguchi et al., 2014). This relationship may
serve as the mechanism for the elevated and resistant state of FGF-21 in
obesity.
In relation to exercise, FGF-21 is influenced by both the sympathetic activation of
exercise and muscular contraction. Basal concentrations of FGF-21 are not
influenced by sympathetic inhibition via administration of clonidine, yet increases
during hypoxia-induced sympathetic activation and its concurrent increase in
circulating epinephrine (Scalzo et al., 2014). Any increase in FGF-21 due to
hypoxia was abrogated with the co-administration of clonidine, solidifying the
causal nature of sympathetic input for the release of FGF-21. It is likely that
exercise-induced FGF-21 is highly related to epinephrine and lipolysis because
sympathetic inhibition does not affect basal FGF-21, yet acute activation of the
sympathetic system does (Scalzo et al., 2014). Humans undergoing either a 50
or 80% VO2max treadmill run for 30 min have been observed to induce an
increase in plasma FGF-21 one hour after the cessation of exercise (Kim et al.,
2013). At one h there was also a significant difference between the 50% and
80% VO2max tests, indicating a potential dose-response relationship between
exercise intensity and FGF-21 secretion. Kim et al. (2013) also measured peak
FFA concentrations, which occurred immediately after exercise. Considering that
immediate response of FFA and the delayed increases in FGF-21, it is likely that
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the FFA response of exercise may be the cause of the subsequent release of
FGF-21. Contrary to these findings, Cuevas-Ramos et al. (2012) found no acute
changes in plasma FGF-21 concentrations at one and four h after a treadmill
ramp test producing an energy output of 22 metabolic equivalents (energy
required as measured by oxygen consumption for resting/basal metabolism) at
its peak. In the same study conducted in overweight women, aerobic training in
the form of nine treadmill ramp tests caused resting FGF-21 to increase as well
as epinephrine and FFA. Considering that the FGF-21 gene is responsive to the
effect of FFA on the PPAR-α transcription factor, it may be due to increased
lipolysis and its resulting increase in circulating FFA. It was postulated that FGF21 becomes elevated to increase lipid metabolism to prevent any ectopic
deposition of lipid that may be caused by the increase in FFA post exercise
(Cuevas-Ramos et al., 2012). Additional training studies have found that a
combined aerobic and resistance training program consisting of 45 min of
aerobic training at 70% of age predicted maximum heart rate and 20 min of
resistance training caused a 44% reduction in resting plasma FGF-21 after three
months (Yang et al., 2011). The training was conducted five d per week for 12 wk
which also resulted in a significant decrease in body mass index, indicating the
decline in resting FGF-21 may be induced by a loss of body fat (Yang et al.,
2011). A sprint training modality has also been studied where an interval exercise
program consisting of four-eight, 30 sec, all-out sprints caused a reduction in the
resting concentration of FGF-21 after nine sessions of training (Scalzo et al.,
2012).
From the studies outlined above, FGF-21 appears to be a myokine that is an
early indicator of obesity which can be up regulated by mitochondrial
abnormalities and is responsive to exercise and exercise training. FGF-21 is
capable of inducing an oxidative phenotype and is responsible for shifts in
adipose phenotypes. It is possible that FGF-21 is a response to the adrenergic
and lipolytic effects of exercise, but these conclusions are currently unclear. The
relationship between FGF-21 and exercise has not been thoroughly researched
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and thus focus on this myokine is warranted, specifically in the area of both SIE
and SIT.

2.4

Interleukin-15

Discovered in 1994 by Grabstein et al. and Giri et al., Interleukin-15 (IL-15) is a
59 amino acid member of the four α-helix family of cytokines. IL-15 was originally
identified as a T-cell growth factor of the immune system which interacts with
subunits of the Interleukin-2 receptor (Grabstein et al., 1994). IL-15 was first
implicated in the function of muscle when it was found to be highly expressed in
muscle (Grabstein et al., 1994) and when the treatment of IL-15 induced the
accretion of myosin heavy chain proteins in murine and bovine myocytes (Quinn
et al., 1995). Based on the findings of these original studies, IL-15 was classified
as an anabolic growth factor.

2.4.1

Cell Studies

Cell studies focusing on the effects of IL-15 have been able to show both an
anabolic role and the ability to induce an oxidative phenotype in muscle. In one
of the original papers recounting the anabolic effects of IL-15, Quinn et al. (2002)
described the induction of hypertrophy independent of IGF-1 in differentiated
myotubes from mice. Over-expression of IL-15 in same-cell lineage via retroviral
injection of the IL-15 gene into the cells resulted in 400-fold greater concentration
of myosin heavy chain and alpha-actinin accretion. The hypertrophic effect
occurred without proliferation of myoblasts, indicating a sarcoplasmic
hypertrophic response. It is important to note that the treatment of IL-15 also
prevented the degradation of protein within the cultured myotubes, making a
conclusion related to any increase in protein synthesis difficult. Furmanczyk and
Quinn (2003) were able to replicate the previous findings regarding the ability of
IL-15 to induce the accretion of myosin heavy chain protein within differentiated
human myotubes and muscle fibres. These data are consistent with both studies
from myogenic precursor and rodent studies, demonstrating an anabolic effect of
IL-15.
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The effect of IL-15 on lipid deposition and oxidation is also pronounced within cell
studies. By treating murine 3T3-L1 adipocytes with recombinant IL-15, Quinn et
al. (2005) were able to reduce lipid deposition by more than 50% and stimulate
the release of adiponectin. These findings prompted the authors to conclude that
there is a direct modulating effect of IL-15 on the function of adipose tissue and
there is a communication axis between muscle and fat. Furthermore, O'Connell
and Pistilli (2015) found that the treatment of muscle cells derived from mice with
recombinant IL-15 had a distinct and significant increase in PGC-1α and PPAR-γ
expression and greater mitochondrial density when compared to control cell
lines. These findings indicate that IL-15 may be able to not only reduce the
accretion of adipose tissue, but also enhance β-oxidation of circulating lipids in
skeletal muscle.

2.4.2

Animal Studies

The role of IL-15 within animal models has been studied extensively in both rats
and mice. When compared to wild-type mice, transgenic mice over-expressing
IL-15 have been described as having both elevated muscle IL-15 protein and
circulating IL-15 in plasma (Quinn et al., 2013). In a treadmill run to exhaustion,
the IL-15 transgenic mice ran twice the length of time to fatigue when compared
to wild type mice and also had a lower amount of visceral adipose tissue. In the
same study, indirect calorimetry of the IL-15 transgenic mice indicated that the
over-expression of IL-15 induced a lower RER suggesting the mice utilized a
greater proportion of fat as primary energy substrate. Alongside the overexpression of IL-15, there was also increased expression of oxidative regulators
such as PGC-1α, an increase in the oxidative Myosin Heavy Chain Type I and
markers of mitochondrial lipid oxidation, indicating an induction of oxidative
adaptations associated to exercise. In a continuation of the previous study, IL-15
knockout mice did not show any up-regulation of PGC-1α, SIRT-1 or any other
pro-oxidative mediators after undergoing a bout of exhaustive exercise running
(Quinn et al., 2014). Wild type mice exhibiting IL-15 expression also had a much
longer run time to exhaustion. Injection of recombinant IL-15 into the knockout
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mice was able to up-regulate the aforementioned oxidative mediators, suggesting
that many of the oxidative adaptations due to exercise are mediated directly
though IL-15.
IL-15 is present in mammalian systems in two forms, one long and one short
signaling domain peptides. In a study examining the effect of either peptide form
Quinn et al. (2008) identified the short signal peptide as the most efficient
endocrine signal and that any functional changes in body composition are due to
the appropriate signal peptide being secreted into the bloodstream. Elevated IL15 resulted in significantly reduced body fat (50% for males, 25% for females)
and increased bone mineral density. In a group of mice over-expressing the
efficient short signal IL-15 peptide, there were reduced concentrations of
common pro-inflammatory cytokines such as IL-6 in groups that were fed a high
fat diet. In the same study, Quinn et al. (2008) found there was no increase in
muscle protein synthesis under a milieu of IL-15, but a reduction in protein
degradation. This suggests that IL-15 may not be an anabolic factor, but an anticatabolic factor in-vivo.
In 2010, Quinn et al. identified that physiological concentrations of IL-15
decrease with age, but expression of IL-15 mRNA did not. However, the
expression of the soluble IL-15Rα subunit decreased 5-fold with age and
correlated significantly with circulating IL-15. Based on these data, Quinn et al.
(2010) suggested that the α-subunit of IL-15 both influences the secretion of IL15 into circulation and the responsiveness of tissues to IL-15. Lastly, in clinical
populations 12 wk of endurance treadmill running led to an increase in IL-15
expression in the muscle of diabetic rats and also improved intraperitoneal
glucose tolerance (Kim et al., 2013).

2.4.3

Human Studies

In comparison to the myokines outlined above, IL-15 has not been studied to the
same extent in humans. However, IL-15 has been evaluated in the context of
both strength and aerobic training. For strength training, Reichman et al. (2004),
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trained men three days per week for 10 wk. The subjects performed 13 exercises
each, containing four sets of six-10 repetitions at their 80% one-rep maximum.
By studying the effect of different haplotypes for the IL-15 receptor α-subunit, it
was found that 7.1% of the variability of muscle mass gained from the training
was due to a single receptor haplotype, the IL-15 short signal peptide. These
findings are consistent with the findings of Quinn et al. (2008), who found that the
short signal peptide of IL-15 was most efficient as an endocrine signal in animal
models. The strength exercise increased plasma IL-15 acutely both before and
after the 10 wk of training and this effect was still significant when accounting for
any changes in plasma volume due to exercise. In an acute bout of aerobic
exercise, lean and obese subjects exercised on a cycle ergometer for 120 min at
a moderate intensity (55-60% of age predicted maximum heart rate). IL-15 was
increased two-three fold in both lean and obese subjects, with no difference
between the groups as defined by body mass (Christiansen et al., 2013). In a
similar study, 30 min of treadmill running at 70% of age predicted maximal heart
rate in untrained men induced a significant response with a peak plasma IL-15
concentration reached 10 min after the cessation of exercise (Tamura et al.,
2011). The authors concluded that the release of IL-15 was due to contraction
induced stimuli rather than from muscular damage caused by exercise because
the maximum observed creatine kinase response from the exercise was greatest
at three h post-exercise, while the IL-15 concentration was reduced to normal
concentrations at three h. These findings are critical in defining IL-15 as a true
myokine being secreted from muscle as a response to contraction, rather than a
global inflammatory response to exercise stress.
The change in plasma IL-15 due to aerobic training has also been evaluated.
Christiansen et al. (2010), found that an exercise intervention consisting of 12
weeks of tri-weekly aerobic running for ~60 min and an energy expenditure of
500-600 kJ had no effect on circulating IL-15 (with a concurrent loss of three kg
of body fat) in obese subjects. However, the combination of energy restriction
and exercise (with a loss of 12.1kg of body fat) caused a reduction of 25% of
plasma IL-15. This suggests that plasma IL-15 may be related to the absolute
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amount of body fat and in obese individuals and that IL-15 may be chronically
elevated as a marker of inflammation associated with the obese state.
However, there are also instances where exercise has been shown to have no
effect on the concentration of plasma IL-15. In endurance trained athletes,
Ostrowski et al. (1998) found no change in serum IL-15 after 2.5 h of treadmill
running at 75% of maximum oxygen consumption. It is likely that in this situation
the athletes may have had a body fat content that was below a threshold value to
produce IL-15 as proposed by Christiansen et al. (2010) or due to their training
status, the stimuli of the running was not great enough to illicit a myokine
response from the muscle tissue. Neilsen et al. (2007) also demonstrated that
acute, heavy resistance leg exercise was unable to produce a significant
increase in plasma IL-15. However, there was an increase in muscle IL-15
mRNA. These findings allowed the authors to speculate that IL-15 may be
present as a translationally inactive pool. Interestingly, IL-15 mRNA was
enhanced in muscle groups dominated by Type II fibres, suggesting that
activation of these fibres may result in the specific secretion of IL-15. If so, it is
likely that the intensity of exercise is key to the secretion of IL-15 and very high
intensity weightlifting or sprinting is most likely to induce the strongest myokine
response from muscle.
In summary, IL-15 appears to be a muscle-derived signaling protein that is
capable of inducing both hypertrophy and oxidative adaptations to exercise. It is
possible that IL-15 is dependent on the absolute fat content of the body in
mammalian models and that the beneficial effects of exercise such as increased
fat oxidation and mitochondrial proliferation are directly mediated through IL-15.
Although there is a significant amount of data supporting the function of IL-15 in
animal models, much less research exists in human models. This is particularly
evident in evaluations of sprint exercise, as no studies currently exist profiling the
effect of SIE on the secretion of IL-15.
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3

Methods

3.1 Participants
Twelve exercise-trained men started and nine finished this study (n=9, age 23.3
± 2.4 years, height 177.7 ± 4.9 cm, mass 82.1 ± 11.1 kg, body fat 17.2 ± 8.4%;
mean ± SD). All subjects were recreationally active and participated in regular
strength and/or aerobic exercise ~3 d/wk, but did not follow specific training
programs and were not sprint-trained. Potential participants were excluded if they
had any known metabolic, musculoskeletal or neurological diseases. In addition,
participants completed a PAR-Q (Canadian Society for Exercise Physiology,
2002, Appendix D) and a health information form (Appendix C) to screen out any
potential contraindications to the exercise. Participants could not have engaged
in any sprint interval training (SIT) within two months of the beginning of the
experimental procedures.
All risks and discomforts were explained fully prior to any testing and all
participants provided written, informed consent. This study was conducted in the
Exercise Nutrition Research Laboratory (ENRL) and was approved by the Office
of Research Ethics at The University of Western Ontario.

3.2 Preliminary Visits
Prior to experimental testing, participants were required to visit the ENRL on two
separate occasions for familiarization to laboratory testing procedures and
screening/baseline measures.
On the first visit, participants had their body composition measured and were
familiarized with the computerized, electromagnetically braked Velotron ™ cycle
ergometer (RacerMate, Inc., Seattle, Washington USA), which was used for all
cycling tasks throughout the study (maximal oxygen consumption [VO 2max] and
sprint exercise). Previous research confirmed the power accuracy of the
Velotron™ to be within 3% of the power recorded via a dynamic calibration rig
during high intensity interval exercise (Abbiss et al., 2009). All individual
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adjustments made to seat height, seat distance, handle bar height and handle
bar reach were recorded and used for subsequent tests. Once familiarized,
participants completed a VO2max test.
On a subsequent day and not within 48 hours of the completion of the VO 2max
test, participants completed a familiarization of the experimental sprint protocol.
The protocol was described originally by Burgomaster et al. (2005). Briefly,
participants completed a series of four Wingate tests (30 sec max efforts;
resistance of 9% body mass), with a rest interval of four min separating each
test. During the resting periods, the load against the Velotron™ flywheel was
reduced to zero and participants were given the option of either active or passive
recovery. Each received a three min warm-up on a Monark 874E Erogometer
(Monark, Inc, Vansbro, Sweden) at an absolute resistance of one kg. After the
three min warm-up, the participants were then allotted a two-min stretching
period. During the familiarization session total work output or the area under the
curve of instantaneous power output was recorded as well as peak power output
and anaerobic power. The total work output was recorded for each Wingate
within the familiarization session and added together to represent the total work
output for the sprint session.

3.3 Experimental Overview
Participants underwent two experimental conditions: Sprint Interval Exercise
(SIE) and Continuous Exercise (CE). Each condition consisted of a five h test
day in the laboratory. Conditions were conducted via a systemically rotated,
crossover design and were separated by at least one week. Briefly, the first
participant was assigned randomly to an experimental condition and thereafter
treatments were systematically rotated to avoid order or training effects. Each
subject completed both conditions (SIE and CE).
On the eve of testing, participants were provided a standardized high
carbohydrate pasta meal (two g of carbohydrate∙kg body mass-1) in order to
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minimize the intra and inter-variability of nutritional status (Jeacocke & Burke,
2010). Participants consumed the pasta meal between 1700-2000 h with no
additional carbohydrates besides 250 mL of their preferred pasta sauce.
On test days, participants reported to the ENRL at 0800 h after a 12 h overnight
fast having been instructed to not exercise or consume alcohol for 24 h prior to
testing and no caffeine on the morning of the test day. Participants were given a
standardized breakfast 0830h (~25 kJ∙kg-1 body mass) which consisted of 10
kJ∙kg-1 of Dempster’s® Original 100% Whole Wheat Bread (Maple Leaf Foods
Inc., Toronto, Ontario), 11 kJ∙kg-1 of Kraft® Smooth peanut butter (Kraft Canada
Inc., Don Mills, Ontario) and 200mL of Tropical Grove Apple Cocktail (Lassonde
Beverages Canada, Toronto, Canada).
At 0805 h, a resting venous blood sample was taken directly into a four ml EDTA
vacutainer. A second one ml sample was taken by a polyurethane syringe
directly from the catheter into which it was aliquoted into triplicate 70-microlitre
hematocrit samples, used to determine any changes in blood plasma
concentration. This sampling procedure was repeated for all time points at which
a blood sample was taken. At 0925 h, subjects completed an exercise warm-up
that was identical to that of the SIE familiarization day. At 0930h subjects
completed either the SIE session or a work-matched (Joules) CE experimental
trial. Four more blood and hematocrit samples were taken as follows: five, 30, 90,
and 180 min after the completion of exercise. At 1115h subjects were fed a
standardized lunch (~17kJ∙kg-1 body mass), consisting of the same ingredients
as breakfast.

3.4 Exercise Protocol
The aim of the experiment was to conduct a work-matched (per-joule basis)
comparison of exercise intensity on the effect of plasma myokine accummulation
between SIE and CE. For this project, exercise intensity is referred to as a
percentage of measured VO2max. To do this the exercise protocols were designed
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to have the same total work output. The length of the CE session was thus
determined by the total work output from the SIE familiarization session or the
SIE experimental trial in the situation where the systematic rotation of the
experimental trials determined that the SIE trial was performed first.

3.4.1

Continuous Exercise Trial

The intensity of the CE trial was set at a load that would elicit a VO2 response of
~65% of VO2max because this is a moderate intensity and is common for many
aerobic exercise training regimes (American College of Sports Medicine. ACSM
Guidelines for Exercise Testing and Prescription. Whaley MH, ed. 7th ed.
Philadelphia, PA: Lippincott Williams & Wilkins; 2006). The load of the CE trial in
kgm∙min-1 was determined using the following equation:

Note that for this experiment that MET (Metabolic Equivalents) was set to a value
of 2.6 ml of O2∙kg-1∙min-1 as it has been shown that the traditional value of 3.5 ml
of O2∙kg-1∙min-1 is a significant overestimation and that 2.6 is a more accurate
value (Byrne et al., 2005, McMurray et al., 2013). Metabolic Equivalents are
defined as the as energy required for basal/resting metabolism as measured by
oxygen consumption. The VO2max value was taken from the VO2max test that all
participants completed during their preliminary visit to the laboratory.
Once the load for the CE trial was determined in kgm∙min-1, it was converted to
watts using the equation:

The length of the CE trial was then calculated using the total work output in
Joules from either the familiarization trial or the SIE experimental trial, depending
on the participant’s order of experimental trial rotation. The length of the CE trial
in sec was determined using the following equation:
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OR

The CE was then conducted on the Velotron™ cycle ergometer interfaced with
computer based, interactive Coaching Software (RacerMate Inc, Version 1.15).
The Coaching Software’s ergometer mode ensured participants maintained the
prescribed workload irrespective of cadence. Participants were provided with a
schematic profile of power output throughout the trial as well as real-time
feedback of time elapsed and time remaining.

3.4.2

Sprint Interval Exercise Trial

The SIE trial was conducted as described by Burgomaster et al. (2005),
consisting of a series of four Wingate tests each separated by four min of
recovery. The Wingate cycle test is a computerized measure of anaerobic power,
described originally by Barr-Or and colleagues (1977). Briefly, participants sat on
the Velotron ergometer and cycled as fast as possible for 30 sec against a
flywheel resistance set to 9% body mass in kg. Total work output, peak power
(highest power output over any five sec) and anaerobic power were determined
using an online data acquisition system (Computrainer, RacerMate Inc, Seattle,
WA). As explained earlier, the load against the flywheel during the recovery
periods was set to zero so that the subject’s choice of active recovery would not
affect the total work output.
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3.5 Measurements
3.5.1

Body Composition

Air displacement plethysmography body volume (BodPod®) and body mass were
used to determine body density. Participants were required to fast three h prior to
entering the BodPod®, and to wear approved clothing (compression shorts and
lycra swim cap) to minimize errors due to air in hair or under clothing. Thoracic
volume was estimated via a calculation integral to the BodPod® software. In order
to estimate body composition, the attained body density was imputed into the Siri
(Siri, 1961) equation

3.5.2

Aerobic Capacity

VO2max was determined via a 25 W∙min-1 incremental ramp protocol on a
Velotron™ cycle ergometer. Briefly, the ramp protocol consisted of a two min
warm-up at a self-selected wattage followed by an increase to an initial
resistance of 90-125 W (depending on body mass) with subsequent five W
increases every 12 sec. Expired gases were collected via a breath-by-breath
collection system (Sensormedics Vmax 29, Yorba Linda, CA). The greatest value
achieved over a 30 sec collection period was considered max whenever a
plateau in VO2 occurred (<50% of the expected increase in oxygen uptake for the
increased workload) or when two of the following three criterion measures were
attained (95% of age predicted maximum HR, RER >1.15 [RER = volume of CO 2
produced/volume of O2 consumed] or volitional exhaustion).

3.5.3

Blood Sampling and Hematocrit

To determine any changes of plasma myokines concentration, blood samples
were taken pre-exercise, five, 30, 90 and 180 min post- exercise. All venous
blood samples were drawn by a certified nurse, who employed standard sterile
blood handling techniques to prevent infection or contamination. Prior to any
specimen collection, the participants were debriefed regarding the blood draw
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process as well as informed of the procedure in place in case of an adverse
reaction.
Prior to exercise a 20 gauge indwelling catheter (BD Angiocath™, Becton,
Dickinson and Company©, New Jersey, USA) was inserted into a vein in the
antecubital area of either one of the subject’s arms and an IV set three-way
stopcock (MED-RX®, Benian Inc., Oakville, Canada) was attached. For any of
the blood samplings, blood was drawn into a four ml BD Vacutainer ® EDTA
collection tube (Lavender top, Becton, Dickinson and Company©, New Jersey,
USA), inverted eight times and immediately centrifuged. The vacutainers were
centrifuged for 10 min at 3000x g at four°C (Allegra™ 21R, Beckman Coulter™,
California, USA). Plasma obtained was aliquoted into two, two ml Eppendorf
tubes (Eppendorf Inc., Mississauga, Ontario) and frozen at -20°C for ~three
weeks and then transferred to -70°C until later analysis. After the blood samples
were taken, two ml of 0.9% Injectable Saline USP (Hospira, Montreal, QC,
Canada) was injected back through the catheter to act as a saline lock to keep
the catheter patent in between samples. Any remaining saline was drawn off
from the catheter using a separate BD Luer Lok™ 3ml syringe (Becton,
Dickinson and Company©, New Jersey, USA) and discarded before any
Vacutainer samples were taken.
For hematocrit, an additional one ml of blood was drawn into a BD Luer Lok™
one ml syringe (Becton, Dickinson and Company©, New Jersey, USA) and then
drawn via capillary action into Drummond® Heparinized microcapillary tubes
(Drummond Scientific Co. Broomall, PA, USA). The microcapillary tubes were
then sealed at one end by Critoseal® (Oxford Labware®, St. Louis, MO, USA).
The microcapillary tubes were centrifuged for three min in a Triac™ Hematocrit
Centrifuge (Clay Adams, Division of Becton, Dickinson and Company©, New
Jersey, USA). The centrifuged microcapillary tubes were then measured against
a ruler to determine the Packed Cell Volume (PCV) as a proportion of the total
volume within the microcapillary tube. The PCV was used to determine any
changes in plasma volume due to the pressure gradient effects of exercise (Van
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Beaumont, 1972). Plasma volume may also have been affected by osmotic
pressure due to the effect of exercise metabolites increasing in concentration
within the cellular compartment. These two factors were considered when
analyzing any changes in plasma volume.

3.5.4

Blood Analysis

Blood was analyzed and myokines were quantified using commercially available
Enzyme-Linked Immunosorbent Assay (ELISA) Kits. FGF-21 and IL-15 were
measured using the Human FGF-21 and IL-15 Quantikine ELISA kits (R&D
Systems, Minneapolis, Minnesota, USA). Irisin was measured using Phoenix
Pharmaceuticals Inc. Irisin ELISA assay kit (EK-052-67).

3.6 Statistical Analysis
Statistical analyses were conducted using SigmaPlot for Windows (Version 12.0).
All data were analyzed using a two-way repeated measures ANOVA (condition x
time). Tukey’s HSD was used for post-hoc analysis to determine any significant
effects. In order to determine effect sizes, a partial eta-squared analysis was
conducted. Linear regressions were also performed to determine any association
between, fat mass, lean mass and the absolute peak concentration of plasma
myokines. Significance was set at p ≤ 0.05. Data are presented as means ± SD.

38

4

Results

4.1 Descriptive Statistics
Of the original 12 participants, three could not finish the entire study. One subject
withdrew due to an illness unrelated to the study and two others withdrew
because they relocated away from the London area. Subject 6 was eliminated
from all analyses because all samples consistently had negative absorbances
and thus below zero concentrations of myokines. Subject 9 was removed from
the Irisin analysis due to the fact that its ELISA readings were also all negative
absorbances. The catheters clotted at the following timepoints and thus no
samples were obtained: Subject 2 and 11 at 180 min in sprint condition and
subject 2 and 3 at 180 min in the endurance condtion. Subject 8 also temporarily
clotted 5 min post endurance condition. The clot did not remain and thus it was
the only data point that was lost.
The training history of the participants was varied. Of the participants three were
competitive power lifters, one was a trained hockey player, one was a
competitive ultimate frisbee athlete and four others exercised approximately
three days per week, but did not follow specific aerobic or resistance training
programs. It must be noted that only one of the subjects elected to choose active
recovery while resting between sets of Wingates while performing the sprint
condition.
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Table 4.1. Participant characteristics and performance test results
Participant
#

Age
(years)

Mass
(kg)

Height
(cm)

Fat
Mass
(kg)

Body
Fat
(%)

182.0
183.0
178.0
180.5
167.0
175.0
177.0
182.0
174.5

Lean
Body
Mass
(kg)
76.0
69.0
67.2
81.1
62.5
65.1
67.3
56.3
63.6

1
2
3
4
6
7
8
9
11

25
25
22
22
23
22
24
19
28

90.1
98.2
79.0
89.5
67.6
86.9
83.4
60.0
84.5

Mean

23.3

SD

2.4

SIE Trial
Work
output
(J)
81902.2
85149.7
65882.0
91924.8
60573.0
65640.0
64410.2
43106.2
60409.7

65%
VO2max
(W)

15.6
29.7
20.2
9.8
5.4
25.1
19.5
5.2
24.7

VO2max
(mL O2
-1
•kg
-1
•min )
58.3
42.7
49.7
61.1
56.8
41.8
38.9
52.0
35.1

255
184
182
267
185
160
143
147
135

Length
of CE
Trial
(min)
5.41
7.71
6.03
5.74
5.45
7.89
7.52
5.19
7.18

14.1
29.2
15.8
8.8
3.6
21.9
16.3
3.1
20.9

82.1

177.7

67.1

14.9

17.2

48.5

68777.5

184.2

6.55

11.1

4.9

7.1

8.1

8.4

8.7

13452.7

44.7

1.00

Values are mean±SD; y = years; kg = kilograms; cm = centimetres; % = percent;
min = minutes; VO2max = maximal oxygen uptake; J = joules; W = watts
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4.2

Hematocrit and Hemoconcentration

There was no significant main effect of time or exercise condition. There was a
significant interaction effect (exercise condition x time; p= 0.04). Pairwise
comparisons (Tukey) indicated that PCV was significantly greater at 5 min postexercise with SIE condition when compared to CE condition (p<0.001). At 5 min
post SIE, PCV increased from 46.4 percent to 51.9 percent. The CE condition
had no significant effect on PCV. Neither exercise condition was significantly
different at any other time point (Fig 4.1).
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Figure 4.1. Hematocrit changes after SIE or work-matched CE as denoted
by Packed Red Blood Cell Volume as percent of total microcapillary tube
volume. (* = p<0.05) Data are means mean ±SD (n=8).
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Table 4.2. Percent changes in plasma volume after SIE or work-matched
CE.

5 min post

30 min post

90 min post

180 min post

exercise

exercise

exercise

exercise

SIE

-19.5

2.8

-6.0

2.1

CE

-5.2

3.8

-2.8

4.7

The change in plasma volume (%ΔPV) was calculated with the following
equation:

Effect size estimates (ɳ2) indicated that 6% of the variability in hematocrit was
due to exercise condition and 11% of the variability was due to time. These
values translate to medium-large effect sizes.
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4.3

IL-15

There was no significant main effect of time (p=0.55) or exercise condition
(p=0.71) on the plasma accummulation of IL-15. There was also no significant
interaction effect (condition x time, p=0.34) (Fig 4.2). Further, due to a high
degree of variability within duplicates from the IL-15 ELISA assay, IL-15 was
excluded from any remaining analysis.
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Figure 4.2. Change in plasma IL-15 concentration (pg/ml) with SIE or workmatched CE. Data are presented as a mean± SD, n=8
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4.4

Irisin

There was no significant main effect of exercise condition (p=0.18), time (p=0.28)
or interaction effect (p=0.32) (Fig 4.3).
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Figure 4.3. Change in plasma Irisin concentration with SIE or work-matched
CE. Data are presented as means ±SD, n=7.
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4.4.1

Irisin and Body Composition

Plasma Irisin concentration correlated significantly with lean body mass at rest
(Correlation coefficient = 0.78, p=0.001, r2=0.6; Fig 4.4). After exercise, plasma
Irisin was not correlated to muscle mass at either 5 min post exercise or 180 min
post exercise.
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Figure 4.4 Correlation between lean body mass and resting plasma Irisin
concentration. Correlation coefficient = 0.78, p=0.001, r 2=0.6, n=7.
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Figure 4.5. Correlation between lean body mass and plasma Irisin 5
minutes post-exercise under either SIE or CE paradigm. Correlation
coefficient=0.40, p=0.17, r2=0.32, n=7. Subject 8 in the sprint condition is
missing.
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Figure 4.6. Correlation between lean body mass and plasma Irisin 180
minutes post-exercise under either SIE or CE paradigm. Correlation
coefficient=0.44, p=0.20, r2=0.19, n=5.

4.5

FGF-21

There was no significant main effect of time or exercise condition. There was a
significant interaction effect (condition X time), p=0.04). Pairwise comparisons
(Tukey) indicated mean plasma FGF-21 concentration was elevated significantly
at 30 min (p<0.001) post-exercise within the sprint interval condition (Fig 4.7). At
this time point, mean plasma FGF-21 rose from 49.4 ng/ml at rest to 107.64
ng/ml. Further, at 30 min after exercise, SIE induced a significantly greater
plasma FGF-21 concentration (p=0.03) vs CE, with a mean difference of 57.2
ng/ml between SIE and CE. Continuous exercise had no significant effect on the
accumulation of FGF-21.
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Figure 7. Change in plasma FGF-21 concentration with SIE or workmatched CE. All data are presented as mean ±SD. * indicates that the
concentration of FGF-21 is significantly greater than rest within the sprint
interval group (p=0.04, p<0.001). # indicates significantly greater
concentration of plasma FGF-21 for SIE vs CE at 30 min post-exercise
(p=0.03), n=8.
Effect size estimates (ɳ2) indicated that 3% of the variability in plasma FGF-21 is
due to exercise condition, 11% is due to time and 5% due to the interaction effect
(exercise condition x time). These translate to small, medium and small effect
sizes, respectively.
All correlations between plasma FGF-21 and body fat %, lean body mass or fat
mass at rest or post-exercise were nonsignificant.
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5

Discussion

The primary finding from the present study is that an acute bout of SIE increased
plasma FGF-21 significantly at 30 min after the cessation of exercise. Further,
the SIE bout increased plasma FGF-21 significantly at 30 min post-exercise vs
CE, suggesting a physiological difference in the capacity to induce a systemic
FGF-21 response between the two exercise modes. In contrast, there was no
significant effect of either exercise mode on Irisin or IL-15 plasma concentration.
However, Irisin was correlated positively with lean body mass at both rest,
suggesting that total muscle mass may influence systemic Irisin concentrations.
Interestingly, this relationship was no longer present post-exercise. IL-15 and
FGF-21 were not significantly correlated to any body composition parameter.

5.1 IL-15
This is the first study to examine the effects of SIE on the plasma concentration
of IL-15 but neither SIE nor CE altered plasma IL-15 concentration significantly.
However, the results need to be evaluated in context because there was a high
degree of intra-assay variability in duplicate samples as well as variability
between subjects. For this reason, it was difficult to make a definitive conclusion
regarding these data. Some of this variability is likely attributed to sample
preparation because it appeared that some samples were not uniform in their
consistency. Learning from this, all FGF-21 and Irisin samples were vortexed, recentrifuged and aliquoted after thawing to ensure uniformity. Regardless of these
sample preparation issues, some comments about the IL-15 data are
appropriate. Previously published values of plasma IL-15 with endurance
treadmill running and strength exercise in lean, healthy subjects range from ~1.612.6 pg/ml (Christiansen et al., 2013; Riechman et al., 2004; Tamura et al., 2011)
and the current data are similar. Further, compared to the present investigation
(n=9), the previous studies had larger samples sizes; n=13 (Tamura et al., 2011),
n=15 (Christiansen et al., 2013), especially the Reichman et al. (2004) study
(n=76). Consequently, the present observed IL-15 response may have been
nonsignificant due to variability, i.e., a Type II error. Moreover, although the
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current study was designed to isolate the effect of exercise intensity on the
plasma concentration of IL-15, the absence of an increase may suggest that a
minimal exercise duration is necessary for an IL-15 response. Including rest
periods, the present SIE protocol took a total of 14 min (exercise was only 2 min)
and the work-matched CE took only 6.5 min. This is shorter than previously
published studies that reported IL-15 increases. For example, Tamura et al.,
2011 reported significant mean increases from 1.71 pg/ml to 1.95 pg/ml after 30
min of running at 70% of age-predicted heart rate maximum. Although the
intensity of the CE trial in the current study was comparable (65% VO2max) to
Tamura et al. (2001), the total time of exercise was ~5 times less. This same
situation applies to the study by Christiansen et al. (2013), where subjects ran
continuously at a moderate intensity for 60-75 min. Also, using high-intensity
muscular contractions (strength exercise for more than one h duration),
Riechman et al. (2004) observed a significant increase in plasma IL-15. Based
on these findings, it is possible that the secretion of IL-15 is dependent on some
interaction between total exercise time (or volume) and intensity. Clearly, more
study is needed to sort this out.

5.2

Irisin

No significant effect of exercise on the plasma concentration of Irisin was
observed in the current study. From the literature, baseline Irisin concentrations
range from ~90-140 ngl/ml (Huh et al., 2012, Huh et al., 2014, Tsuchiya et al.,
2014, Daskalopoulou et al., 2014). With the present study the mean baseline and
post-exercise values of Irisin concentration were approximately 10-fold less than
published values. Due to the uniformity of this phenomenon and the fact that the
standards from the ELISA kit produced values as expected, it may be that the
low observed Irisin concentrations are the result of an error within the sampling
process. Huh et al. (2012) point out Irisin sample concentrations are unaffected
by freeze-thaw cycles, when stored at -80°C. The current Irisin samples were
stored at -20°C initially for ~three weeks before being transferred to -70 C
storage so, it is possible that some protein degradation occurred, thus reducing
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the concentration of Irisin and perhaps affecting the sensitivity of the experiment
to any changes that may have occurred, regardless of the exercise condition.
Hecksteden et al. (2013) found that Irisin has a degradation rate of 0.184 ng∙ml1

∙day-1 when stored at -20°C. Therefore, although this may have contributed to

some of degradation within our samples, it is unlikely that it is the entire cause for
the low Irisin concentrations because if the degradation rate found by
Hecksteden et al.(2013) occurred, it would have taken 62 wk to produce the
values found within our samples. Obviously, something else was involved. Both
SIE and high intensity exercise in general have been reported to produce 1635% increases in plasma Irisin within 5 min of the completion of exercise (Huh et
al., 2012, Huh et al., 2014, Daskalopoulou et al., 2014). In the current study, SIE
caused no change in plasma Irisin concentration 5 min post exercise, but did
show a 28% increase 3 h post-exercise. Although nonsignificant, this percent
increase in plasma Irisin is similar to previous studies.
Tsuchiya et al. (2014), have suggested that there may be a decrease in plasma
Irisin immediately after high intensity exercise (20 min treadmill running at 80%
VO2max) followed by an increase in plasma Irisin 3 h post-exercise. The present
increase observed with CE at three h post exercise was smaller (12%) when
compared to SIE. As with IL-15 the present results were quite variable and with
the small sample size it is possible that the lack of significant change was the
result of a Type II error.
A significant increase in plasma Irisin 5 min post exercise was anticipated.
However, no such increase in plasma Irisin was observed in either exercise
condition. These findings are surprising in that the work load studied is similar or
greater to those used in the literature. For example Huh et al. (2012),
implemented three sets of two, 80 metre sprints with each set separated by 20
min of rest and reported a 16% increase in plasma Irisin. A second study
investigating six, 50 metre maximal swim sprints with a mean completion time of
~32 sec observed a 30% increase in plasma Irisin, 5 min post exercise (Huh et
al., 2014). The current SIE involved a similar exercise time (four, 30 sec exercise
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bouts) as Huh et al. (2014) but two less exercise bouts. Consequently, it is
possible that our sprinting protocol was below the required exercise duration to
induce an Irisin response, i.e., two additional sets of sprints may have causes a
significant change. The rest/recovery intervals within the Huh et al. (2014) were
similar (5 min) to those of the current study, thus diminishing the likelihood that
the current results were due to rest/recovery interval differences. It is also
possible that the mode of exercise played an important role in the lack of an Irisin
response. Both Huh et al. studies (Huh et al., 2012, 2014), used full-body
exercises in the form of track sprinting and freestyle swimming sprints. These
exercises likely engaged a larger muscle mass in comparison to our study which
was mainly quadriceps dependent (cycling). Further, the convective properties of
water may have influenced these results. Huh et al. (2014) used swimming
sprints and the convective ability of water to draw heat away from the bodies of
the subjects may have artificially lowered body temperature. In conjunction with
FGF-21, Irisin has been found to induce non-shivering thermogenesis through
the uncoupling of the electron transport chain (Lee et al., 2014). So with cooler
body temperatures induced by water, Irisin may have been released into the
bloodstream to contribute to non-shivering thermogenesis. Regardless, the
results of the current study appear to show a reduced effect of exercise on
plasma Irisin vs the literature.
The observation that that resting Irisin is correlated to lean body mass is of
particular interest. These findings are consistent with a previous study which
found biceps circumference as a measure of lean body mass to be correlated
positively with resting plasma Irisin (Huh et al., 2012). Together these data
suggest that a major source of plasma Irisin is skeletal muscle. However, it
cannot be determined that the source of Irisin is skeletal muscle alone because it
could also originate from the motor nerve tissue permeating through skeletal
muscle as suggested by Aydin et al. (2014). If correct, this could have
contributed to the observed reduced Irisin response in the current study because
less motor units would have been active during the cycling exercise used and
thus less nerve tissue was active to contribute to an Irisin response.
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Paradoxically, the correlation between circulating Irisin and lean body mass was
no longer present post-exercise. It is possible that the production of Irisin may be
a result of the basal metabolism of skeletal muscle. Therefore at rest, Irisin would
be produced equally among all muscle tissue and be correlated to lean body
mass. When exercising, it is likely that ATP is diverted away from homeostatic
functions such as myokine production and shunted for the purpose of muscle
fibre contraction. Thus, the linear relationship would be abrogated, producing the
results that were observed within our current study.
The training history of the subject may have played a role in the results. Many of
the subjects regularly participated in strength and resistance training and it could
be thus assumed that they would have had a larger proportion of Type IIx muscle
fibres. It has been shown that in untrained individuals, plasma Irisin is related to
the proportion of Type I fibres (Ellefsen et al., 2014). However, the same study
showed that the relationship between Irisin and Type I fibres was no longer
present after 12 weeks of whole body resistance training. It is likely that the
participants within the current study had approximately the same amount of
resistance training profiled by Ellefsen et al., and thus plasma Irisin would not be
related to their fibre type composition. Physical fitness appears to have no effect
on the acute accumulation of Irisin or other myokines. Huh et al, 2014, found that
there was no difference in the acute accumulation of Irisin after a treadmill run to
exhaustion in relation to participant VO2max. This suggests that the results of the
current study was not dependent on the cardiorespiratory fitness of the subjects.
Although the literature suggests this conclusion, it is imperative that for further
studies a precise training history would be taken and that subjects would be
matched on training history and VO2max.

5.3

FGF-21

The present study has shown that there is a significant effect of SIE on the
plasma concentration of FGF-21. At both 5 and 30 min post exercise, there was
a significant increase in plasma FGF-21 concentrations. Further, at 30 min post
exercise, the SIE response was significantly greater than CE. These findings
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suggest that there is a physiological difference between SIE and CE relative to
plasma FGF-21 accumulation. Finally, current baseline measures of FGF-21
compare favourably to published values at approximately the same daily time
(10:00h, 50-60 ng/ml) (Lee et al., 2013). Peak FGF-21 concentrations occur at
0800h and reach a minimum at 1700h (Lee et al., 2013). Following this trend, the
natural variation of plasma FGF-21 would be decreasing during the sampling
period of the present study. Therefore, it is likely that the increase in plasma
FGF-21 concentration was due to exercise and not the natural diurnal rhythm of
FGF-21.
Moreover, it is likely that there is a dose-response relationship between exercise
intensity and the subsequent plasma concentration of FGF-21 because SIE
caused a significantly greater FGF-21 response in comparison to CE. These
findings are in congruence with those of Kim et al. (2013), who found that 30 min
of treadmill running at 80% VO2max induced a 60% greater FGF-21 response than
30 min at 50% VO2max. It is therefore plausible that as length and intensity of
exercise increases, so too will the plasma concentration of FGF-21.
It is important to rule out any possible effect of reduced plasma volume that may
be the underlying cause for the significant increase in plasma FGF-21
concentration within the sprint interval condition. There was a significant increase
in hematocrit and thus a significant decrease in plasma volume within the sprint
condition 5 min post-exercise. This is caused by the increase in intramuscular
pressure due to exercise, causing an increase in mean arterial pressure and thus
an efflux of fluid from the plasma compartment. Another important factor is the
increase of osmotic pressure from the muscular compartment due to increased
exercise metabolites within the muscle that had not reached equilibrium with the
plasma. The change in plasma volume at 5 min post-sprint therefore influenced
the concentration of FGF-21 and after correction for these plasma volume
changes, no significant difference was found. 30 min-post exercise, there was no
significant change in hematocrit or plasma volume, thus the increase in FGF-21
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concentration at this time point is likely not attributable to any change in plasma
volume.
Some data suggest that cardiorespiratory fitness can play a role in the
determination of FGF-21 concentration, i.e., resting FGF-21 has been inversely
related to VO2max (Taniguchi et al., 2014). Therefore it is possible that the wide
range of cardiorespiratory fitness of the present subjects (35-61.1 ml∙O2-1∙kg1

∙min-1) may have limited the absolute responses to exercise within each subject.

This range of responses may have therefore confounded any other mean
observable changes in FGF-21 concentration.
Since there was an observed increase in FGF-21 concentration with SIE, it is of
interest to speculate about possible mechanisms behind this response to
exercise. First, it is possible that FGF-21 is produced by contracting muscle, but
the observed increase in plasma FGF-21 concentration could also be an indirect
response to exercise. For example, Scalzo et al. (2014) showed that baseline
FGF-21 concentration is not determined by basal sympathetic input, but will
increase in response to hypoxia-induced sympathetic activation. When the
hypoxia-induced sympathetic activation was inhibited by the administration of
clonidine (a central acting adrenergic agonist), the subsequent increase in FGF21 concentration was also eliminated (Scalzo et al., 2014). Therefore it appears
that sympathetic activation is necessary for the accumulation of FGF-21 and that
sympathetic activation during exercise may be a primary cause for the
accumulation of FGF-21. Second, Kim et al. (2013) have shown that peak FGF21 concentration is observed ~one h post-exercise and ~one h after peak blood
FFA is reached. Cuevas-Ramos et al. (2012) have proposed that because the
PPAR-α transcription factor (which plays a significant role in the regulation of the
FGF-21 gene) is stimulated by FFA, it is lipolysis that causes the induction of
FGF-21. If so, this could explain the latency (30 min -one h) in which peak FGF21 concentrations are reached. Therefore, it may be that the increase in FGF-21
was due to the sympathetic activation and associated lipolysis of SIE. FGF-21 is
highly expressed within the liver (Bae et al., 2014; Nishimura et al., 2000), as well
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as its co-receptor, β-Klotho. As theorized by Cuevas-Ramos et al. (2012), FGF21 is produced by the liver in response to increasing FFA to increase lipid
metabolism in order to prevent the ectopic deposition of lipids that had been
liberated as a result of exercise. Therefore from these findings, it is possible to
suggest that FGF-21 can be used as a surrogate measure for sympathetic
activation and lipolysis associated to exercise. This theory may also help explain
the dramatic fat loss associated with regular SIT, in that a greater amount of
lipolysis may occur within each acute bout of training, as exemplified by relative
increases in circulating FFA.

5.4

Limitations

There a few important limitations to this study that need to be addressed. As
mentioned, the study itself was relatively underpowered. Consequently, it is
possible with a sample size of 9 that the statistical analyses were subjected to
potential Type II errors. The present ELISA results also proved to be highly
variable. This needs to be eliminated. Attempts were made to minimize the
errors made in the IL-15 sample preparation with the Irisin and FGF-21 analyses,
but additional steps for sample preparation should be taken including: 1) prechilling EDTA tubes with ice baths before taking blood samples and 2) consistent
freezer storage at -80°C. In the present study, some samples were stored at 20°C and then transferred to the colder freezers. It is possible that there was a
degree of protein degradation due to storage temperature that may have affected
the absolute values of myokine concentrations within our samples. These
limitations make definitive conclusions regarding the acute effect of exercise
mode on plasma myokine accumulation difficult.
Further, into the future, it is important to test the effect of SIT to determine
whether any training adaptations alter the acute response of FGF-21 to SIE. It is
possible that the observed changes within the current study may be altered with
training and this needs to be determined.
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5.5

Future Directions

Based on the current findings, further studies on the effect of SIE on the
accumulation of FGF-21, Irisin, and IL-15 in plasma are warranted due to the
errors made with sampling. Second, it is necessary to determine if the acute SIE
is abrogated by the administration of clonidine to determine if the secretion of
FGF-21 is dependent entirely on the sympathetic activation of exercise. Third,
FFA could also be measured with SIE to document any relationship between
circulating FFA and plasma FGF-21. Fourth, it is would be of interest to
determine whether PPAR-α is up-regulated by acute SIE to determine the
molecular regulators and mechanisms behind the production of FGF-21 after
exercise. Fifth, SIT studies should be completed to determine if the acute effect
of SIE on plasma FGF-21 is altered with training. Sixth, assessing different SIE
modalities, including running, swimming, cycling and strength exercise would be
of interest to determine how plasma myokine concentration is affected by
exercise modality. Seventh, increasing work volume studies should be
investigated because if IL-15 and Irisin are dependent on a threshold volume of
exercise, it might not have been met with the current study. This could be
accomplished through additional sprint sets or alternatively, using a predetermined CE protocol i.e. (15 min at 60% VO2max) to then determine the
~number of sprints to match work outputs. It is also important to match the
subjects based on training history to determine if there is any effect on the acute
accumulation of myokines. This way any variability based on fibre type
composition may be eliminated. Eighth, assessing the capture of myokines
against a known concentration. This would require spiking a blood sample with a
known concentration and processing it with the exact same aliquoting and
storage procedure. This will help determine to what extent the yield from the
blood sampling was accurate for our results. Finally, muscle biopsies might be
utilized to determine if the change in IL-15 is localized more directly within the
muscle tissue for paracrine/autocrine signaling, rather than serving as an
endocrine molecule. This may apply to myokine protein production or perhaps
the induction of its respective mRNA. It is not possible to conclude that the total
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change in plasma myokine concentration is attributable to production alone
because plasma concentration is a net result of production and degradation.
Microdialysis may be one technique that could be used to determine the
production of myokines. Acting similarly to a capillary bed, microdialysis probes
are capable of measuring solutes flowing directly out of a tissue. The
implementation of this technique would allow for the determination of myokine
production directly from the tissue without interaction with the plasma.

5.6

Summary and Conclusion

Nine young, physically active men completed four, 30 sec sprints and a workmatched continuous interval bout at 65% VO 2max on an electromagnetically
braked cycle ergometer. Changes in plasma concentration of three myokines
were measured via ELISA assays: IL-15, Irisin and FGF-21. In contrast to the
experimental hypothesis, IL-15 and Irisin showed little effect of either exercise
treatment; however, plasma FGF-21 was elevated significantly with SIE.
Specifically, at 5 (p=0.039) and 30 min (p<0.001) post-SIE, plasma FGF-21 was
increased. At 30 min post exercise, this observed FGF-21 increase was greater
vs the work-matched CE condition (p=0.03).
These results suggest that SIE elicits a physiologically different response to
exercise when compared to CE at least with FGF-21. They also indicate that per
joule of work, sprint interval exercise is capable of generating a significantly
greater systemic FGF-21 response. Moreover, elevated FGF-21 may indicate
that there is a greater fatty acid release during SIE because FGF-21 may be a
surrogate measure of sympathetic activation during exercise. Therefore, it is
possible that the fat loss associated with SIT may be related directly to the
amount of FFA generated during and following each acute sprint interval training
session.
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